Literature DB >> 27510261

Heart failure in elderly patients: differences in clinical characteristics and predictors of 1-year outcome in the Polish ESC-HF Long-Term Registry.

Krzysztof Ozierański, Paweł Balsam, Agata Tymińska, Michał Peller, Agnieszka Kapłon-Cieślicka, Michał Marchel, Jarosław Drożdż, Krzysztof J Filipiak, Grzegorz Opolski.   

Abstract

INTRODUCTION    Heart failure (HF) is the leading cause of hospitalization in elderly patients. OBJECTIVES    The aim of the study was to examine the clinical profile and 1-year outcomes of elderly patients (aged ≥65 years) compared with younger patients (aged <65 years) hospitalized for HF decompensation, as well as clinical differences among elderly patients aged 65-74 years and those aged ≥75 years. PATIENTS AND METHODS    The primary endpoint (PE; all-cause death) and the secondary endpoint (SE; all-cause death or rehospitalization for HF worsening) were assessed at 1 year in a group of 765 hospitalized Polish participants of the ESC-HF Long-Term Registry. RESULTS    The PE was observed in 9.1% of patients aged <65 years; 18.5% of those aged ≥65 years (P = 0.0001); 14.5% of those aged 65-74 years; and 21.6% of those aged ≥75 years (P = 0.07). The SE occurred in 28.0% of patients aged <65 years; 36.1% of those aged ≥65 years (P = 0.04); 29.2% of those aged 65-74 years; and 41.2% of those aged ≥75 years (P = 0.01). Independent predictors of the PE in patients aged ≥65 years were as follows: chronic obstructive pulmonary disease (COPD), systolic blood pressure (SBP), New York Heart Association (NYHA) class, β-blocker use; in patients aged 65-74 years: coronary revascularization, NYHA class, sodium, and creatinine; in patients aged ≥75 years: NYHA class and SBP. Independent predictors of the SE in patients aged ≥65 years were as follows: COPD, NYHA class, potassium, SBP, and physical activity; in patients aged <65 years: chronic kidney disease (CKD), NYHA, and SBP; in patients aged 65-74 years: NYHA and creatinine; and in patients aged ≥75 years, previous HF hospitalization, coronary artery disease, CKD, COPD, alcohol consumption, smoking, NYHA, and SBP. CONCLUSIONS    Elderly patients with HF differed from younger patients in terms of long-term outcome and prognostic factors. There were also important differences within the elderly group itself.

Entities:  

Mesh:

Year:  2016        PMID: 27510261     DOI: 10.20452/pamw.3490

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  4 in total

1.  In-hospital heart rate reduction and its relation to outcomes of heart failure patients with sinus rhythm: Results from the Polish part of the European Society of Cardiology Heart Failure Pilot and Long-Term Registries.

Authors:  Paweł Balsam; Michał Peller; Sonia Borodzicz; Agnieszka Kapłon-Cieślicka; Krzysztof Ozierański; Agata Tymińska; Michał Marchel; Maria G Crespo-Leiro; Aldo Pietro Maggioni; Jarosław Drożdż; Marcin Grabowski; Krzysztof J Filipiak; Grzegorz Opolski
Journal:  Cardiol J       Date:  2018-08-29       Impact factor: 2.737

2.  Mean Platelet Volume as a Predictor of Heart Failure-Related Hospitalizations in Stable Heart Failure Outpatients with Sinus Rhythm.

Authors:  Hakki Kaya; Mustafa Kutay Yıldırımlı; Recep Kurt; Osman Beton; Mehmet Birhan Yilmaz
Journal:  Acta Cardiol Sin       Date:  2017-05       Impact factor: 2.672

3.  A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan.

Authors:  Hideyuki Takimura; Tasuku Hada; Mami Kawano; Takayuki Yabe; Yukako Takimura; Satoru Nishio; Masatsugu Nakano; Reiko Tsukahara; Toshiya Muramatsu
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

4.  Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction.

Authors:  Jesse F Veenis; Hans-Peter Brunner-La Rocca; Gerard Cm Linssen; Peter R Geerlings; Marco Wf Van Gent; Ismail Aksoy; Liane Oosterom; Arno Hm Moons; Arno W Hoes; Jasper J Brugts
Journal:  Eur J Prev Cardiol       Date:  2019-03-13       Impact factor: 7.804

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.